Evidence map›Paper›PMID 26817504›Full record

ArticleThe American journal of clinical nutrition2016

Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression.

Rebecca E Graff, Andreas Pettersson, Rosina T Lis, Thomas U Ahearn, Sarah C Markt, Kathryn M Wilson, Jennifer R Rider, Michelangelo Fiorentino, Stephen Finn, Stacey A Kenfield and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of clinical nutrition, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 6 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 6 syntheses or guidelines pooled it, 74 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Review
  12. Review
  13. Association of Prediagnostic Blood Metabolomics with Prostate Cancer Defined by ERG or PTEN Molecular Subtypes.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021
    Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 5 countries.

Rebecca E GraffDepartments of Epidemiology, Departments ofEpidemiology and Biostatistics and rebecca.graff@ucsf.edu.
Andreas PetterssonDepartments of Epidemiology, Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden;
Rosina T LisDepartment of Pathology and Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA;
Thomas U AhearnDepartments of Epidemiology.
Sarah C MarktDepartments of Epidemiology.
Kathryn M WilsonDepartments of Epidemiology, Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA;
Jennifer R RiderDepartments of Epidemiology, Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA;
Michelangelo FiorentinoDepartments of Epidemiology, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA; Pathology Unit, Addarii Institute, S Orsola-Malpighi Hospital, Bologna, Italy; and.
Stephen FinnCenter for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA; Department of Histopathology, Trinity College, Dublin, Ireland.
Stacey A KenfieldDepartments of Epidemiology, Urology, University of California, San Francisco, San Francisco, CA; Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA;
Massimo LodaDepartment of Pathology and Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA;
Edward L GiovannucciDepartments of Epidemiology, Nutrition, and Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA;
Bernard RosnerBiostatistics, Harvard T.H. Chan School of Public Health, Boston, MA; Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA;
Lorelei A MucciDepartments of Epidemiology, Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA;
Brigham and Women's Hospital · USDana-Farber Cancer Institute · USInstitute for Medical Informatics and Biostatistics · CHIRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola · ITKarolinska Institutet · SETrinity College Dublin · IE

Funding

Validity of Diet and Activity Measures in WomenP01CA055075 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI WILLETT, WALTER C. · 1991 to 2009
$41.8M
Tumor and Circulating Markers as Links Between Obesity and Lethal Prostate CanceP50CA090381 · NCI · DANA-FARBER CANCER INSTITUTE · PI LODA, MASSIMO · 2002 to 2017
$36.2M
Training Program in Cancer EpidemiologyT32CA009001 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI A. Heather Eliassen, Meir Stampfer · 1985 to 2026
$17.3M
Physicians' Health Study II: Prevention Trial of VitaminsR01CA097193 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI GAZIANO, J. MICHAEL · 2002 to 2011
$15.7M
Cancer Epidemiology Cohort in Male Health ProfessionalsUM1CA167552 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI WILLETT, WALTER C. · 2012 to 2016
$11.5M
Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3U01CA098233 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI HUNTER, DAVID JOHN · 2003 to 2010
$10.8M
Training in Molecular& Genetic Epidemiology of CancerR25CA112355 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WITTE, JOHN S. · 2005 to 2018
$6.5M
Nutritional Epidemiology of Cancer Education and Career Development ProgramR25CA098566 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI STAMPFER, MEIR · 2003 to 2013
$4.5M
Growth Factors and Lethal Prostate Cancer SignatureR01CA141298 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI STAMPFER, MEIR · 2010 to 2013
$2.2M
Sex-Hormones and the TMPRSS2: ERG Fusion in Prostate Cancer ProgressionR01CA136578 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI MUCCI, LORELEI · 2009 to 2013
$1.7M
RANDOMIZED TRIAL OF ASPIRIN AND MORTALITYR01CA040360 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E · 1985 to 2002
$775k
NCI NIH HHS 5P50CA090381NCI NIH HHS CA097193NCI NIH HHS CA136578NCI NIH HHS CA141298NCI NIH HHS CA40360NCI NIH HHS P01 CA055075NCI NIH HHS P50 CA090381NCI NIH HHS R25 CA098566NCI NIH HHS R25 CA112355NCI NIH HHS T32 CA009001NCI NIH HHS T32 CA09001NCI NIH HHS U01CA098233NCI NIH HHS UM1CA167552
6 · The paper itself

Abstract

backgroundThere is limited evidence that supports etiologically distinct molecular subtypes of prostate cancer, the identification of which may improve prevention. Given their antioxidant properties, we hypothesized that lycopene and tomato sauce may be especially protective against diseases harboring the common gene fusion transmembrane protease, serine 2 (TMPRSS2):v-ets avian erythroblastosis virus E26 oncogene homolog (ERG).

objectiveWe aimed to examine associations between estimated lycopene and tomato sauce intake and the risk of prostate cancer defined by ERG protein expression subtype.

designOur study population consisted of a prospective cohort of 46,719 men from the Health Professionals Follow-Up Study. TMPRSS2:ERG was assessed by ERG immunohistochemistry on tumor tissue microarrays constructed from radical prostatectomy specimens. We used multivariable competing risk models to calculate HRs and 95% CIs for the risk of ERG-positive and, separately, ERG-negative disease. We implemented inverse probability weighting to account for evaluating ERG status only in surgically treated cases.

resultsDuring 23 y of follow-up, 5543 men were diagnosed with prostate cancer, among whom 884 were assayed for ERG (426 ERG-positive). With inclusion of only the latter cases, increasing cumulative average tomato sauce intake was associated with a decreased risk of prostate cancer overall (≥2 servings/wk compared with <1 serving/mo; multivariable HR: 0.70; 95% CI: 0.52, 0.95; P-trend = 0.002). With respect to molecular subtypes, cumulative average tomato sauce intake was associated with a decreased risk of ERG-positive disease (HR: 0.54; 95% CI: 0.37, 0.81; P-trend = 0.004) but not with ERG-negative disease (HR: 0.96; 95% CI: 0.62, 1.50; P-trend = 0.10) (P-heterogeneity = 0.04). Increasing quintiles of lycopene intake were associated with a decreased risk of both subtypes (P-heterogeneity = 0.79). Inverse probability weighting did not materially change the results.

conclusionsOur results lend some support to the hypothesis that prostate cancers that harbor TMPRSS2:ERG may be etiologically distinct from fusion-negative cancers. In particular, tomato sauce consumption may play a role in reducing TMPRSS2:ERG-positive disease.

Indexed as

DietAdultAntineoplastic Agents, PhytogenicAntioxidantsCarotenoidsFeeding BehaviorHumansLycopeneMaleMiddle AgedOncogene Proteins, FusionPlant ExtractsProstatic NeoplasmsSolanum lycopersicumTrans-ActivatorsTranscriptional Regulator ERGAntineoplastic Agents, PhytogenicAntioxidantsCarotenoidsERG protein, humanLycopeneOncogene Proteins, FusionPlant ExtractsTMPRSS2-ERG fusion protein, humanTrans-ActivatorsTranscriptional Regulator ERGERG protein expressionlycopeneprostate cancerTMPRSS2:ERGtomato sauce

Identifiers

PMID26817504
PMCPMC4763492
OpenAlexW2262367048

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.